Table I.
Participant demographics
| CMV Seronegative (n = 74) | CMV Seropositive (n = 159) | Statistical Assessment | |
|---|---|---|---|
| Age (y), median ± SD (range) | 85 ± 6.8 (65–93) | 86 ± 7.7 (65–101) | p = 0.1265a |
| Sex (frequency) | 67.6% Female (n = 50) | 69.8% Female (n = 111) | p = 0.7618b |
| Sample size postdose 2 | n = 51 | n = 108 | — |
| Second dose vaccine combination (frequency) | 47.1% Moderna-Moderna (n = 24) 52.9% Pfizer-Pfizer (n = 27) |
35.8% Moderna-Moderna (n = 39) 60.6% Pfizer-Pfizer (n = 66) 2.75% Pfizer-Moderna (n = 3) |
p = 0.2968b |
| Days between dose 1 and dose 2 (mean ± SD) | 32.2 ± 20.8 | 30.4 ± 17.9 | p = 0.6697a |
| Days since second dose to blood collection (mean ± SD) | 179.8 ± 50.1 | 175.4 ± 64.1 | p = 0.9041a |
| Sample size postdose 3c | n = 23 (17 repeated) | n = 51 (30 repeated) | — |
| Third dose vaccine combination (frequency) | 65.2% Moderna-Moderna-Moderna (n = 15) 34.8% Pfizer-Pfizer-Pfizer (n = 8) |
56.9% Moderna-Moderna-Moderna (n = 29) 43.1% Pfizer-Pfizer-Pfizer (n = 22) |
p = 0.6115b |
| Days between dose 2 and dose 3 (mean ± SD) | 203.9 ± 21.0 | 211.7 ± 12.1 | p = 0.2689a |
| Days since third dose to blood collection (mean ± SD) | 82.0 ± 17.3 | 83.7 ± 11.5 | p = 0.7597a |
| Prior COVID-19d | 37.8% (n = 28) | 34.4% (n = 55) | p = 0.6609a |
| Only positive for nasopharyngeal PCR test | 28.6% (n = 8) | 36.4% (n = 20) | p = 0.6244b |
| Only positive for anti-nucleocapsid Abs | 39.3% (n = 11) | 40.0% (n = 22) | p > 0.9999b |
| Positive for PCR test and anti-nucleocapsid Abs | 32.1% (n = 9) | 23.6% (n = 13) | p = 0.7977b |
a
Student t test with Welch’s correction or Mann–Whitney U test by normality.
b
Fisher’s exact test. Comparisons for vaccines postdose 2 were calculated for Moderna-Moderna versus Pfizer-Pfizer.
c
Forty-seven participants had blood drawn postdose 2 and postdose 3.
d
Participants were considered positive for prior COVID-19 infection when they had a recorded positive nasopharyngeal PCR test at a date prior to blood collection and/or seropositivity for anti-nucleocapsid IgG or IgA Abs at time of blood collection for Ab and cellular assays.